Meeting
2016 ASCO Annual Meeting
Benefit of adjuvant chemotherapy and/or trastuzumab in T1ab node-negative human epidermal growth factor receptor 2–positive breast carcinomas: Results of a national multi-institutional study.
Authors
Alexandre de Nonneville
Institut Paoli-Calmettes, Marseille, France
Alexandre de Nonneville , Anthony Goncalves , Christophe Zemmour , Jean-Marc Classe , Monique Cohen , Eric Lambaudie , Fabien Reyal , Sylvia Giard , Roman Rouzier , Richard Villet , Jean-Marie Boher , Gilles Houvenaeghel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 590)
DOI
10.1200/JCO.2016.34.15_suppl.590
Abstract #
590
Poster Bd #
78
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
First Author: Maria Vittoria Dieci
Poster
2020 ASCO Virtual Scientific Program
Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients: HER2/neu 655 polymorphisms, biochemical and clinical features.
First Author: Isabel Blancas
Poster
2019 ASCO Annual Meeting
De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.
First Author: Hadar Goldvaser
Poster
2018 ASCO Annual Meeting
Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial.
First Author: Samuel Martel